European Commission Approves Amgen's New CholesterolLowering Medication Repatha evolocumab The First PCSK9 Inhibitor To Be Approved In The World For Treatment Of High Cholesterol

THOUSAND OAKS Calif. July 21 2015 PRNewswire &160;Amgen NASDAQAMGN today announced that the European Commission EC has granted marketing authorization for Repatha&8482; evolocumab the first proprotein convertase subtilisinkexin type 9 PCSK9 inhibit...